Company Overview

Theranostec develops precision nanomedicines that significantly improve both the delivery and effectiveness of cancer therapies.

Currently, we are at pre-clinical stage with promising anti-cancer effect in vivo animal models. Our near-term plan is to file the IND application to the FDA and initiate clinical trials. Our long-term goal is to seek FDA approval.

We have received several non-dilutive federal funds, including multiple SBIR Phase I and Phase II grants for optimization and IND-enabling studies that will move our two drug candidates into Phase 1 clinical trials.


Founder & CEO: Yuanpei Li, PhD

  • Professor at the University of California, Davis
  • Elected Fellow of the American Institute for Medical and Biological Engineering (AIMBE)
  • Expert in cancer drug development, nanomedicine, and cGMP production.

Co-Founder & COO: Tzu-yin Cindy Lin, DVM, PhD, DACVP

  • Research associated Professor at the University of California, Davis
  • Expert in translational cancer research, Toxicology/Clinical pathology, and nanomedicine.


Edward J. Kim MD, PhD

  • Associate Professor of Medicine
  • Medical Director – Office of Clinical Research, UC Davis Comprehensive Cancer Center
  • Adult medical oncologist who specializes in medical treatment of gastrointestinal malignancies including pancreatic, hepatocellular, biliary, esophageal, gastric, and colorectal cancers.
  • He has expertise in conducting clinical trials for these malignancies and has a particular interest in novel treatments for pancreatic cancer.

Andrew C. Birkeland, MD

  • Surgeon-scientist, Department of Otolaryngology-Head and Neck Surgery, University of California, Davis
  • Expert in the treatment and research of head and neck cancer

Dr. Rick Harkins, NIH CAP advisor

  • Prior Principal Scientist at Bayer Healthcare
  • 35 years experience in the managing partnerships with U.S. academic research institutions and emerging life science firms

Lloyd Kunimoto

  • CEO of Amfora, Inc.
  • 25 years experience in successfully leading biotechnology and biopharmaceutical companies
Scroll to top